PDF(Pubmed)
Abstract：
Large-scale tumor molecular profiling has revealed that diverse cancer histologies are driven by common pathways with unifying biomarkers that can be exploited therapeutically. Disease-agnostic basket trials have been increasingly utilized to test biomarker-driven therapies across cancer types. These trials have led to drug approvals and improved the lives of patients while simultaneously advancing our understanding of cancer biology. This review focuses on the practicalities of implementing basket trials, with an emphasis on molecularly targeted trials. We examine the biologic subtleties of genomic biomarker and patient selection, discuss previous successes in drug development facilitated by basket trials, describe certain novel targets and drugs, and emphasize practical considerations for participant recruitment and study design. This review also highlights strategies for aiding patient access to basket trials. As basket trials become more common, steps to ensure equitable implementation of these studies will be critical for molecularly targeted drug development.
摘要：
大规模的肿瘤分子谱分析表明，不同的癌症组织学是由具有可用于治疗的统一生物标志物的共同途径驱动的。与疾病无关的篮子试验已越来越多地用于测试跨癌症类型的生物标志物驱动的疗法。这些试验导致了药物批准，改善了患者的生活，同时提高了我们对癌症生物学的理解。这篇综述侧重于实施篮子试验的实用性，重点是分子靶向试验。我们检查了基因组生物标志物和患者选择的生物学微妙之处，讨论以前在篮子试验促进的药物开发方面的成功，描述某些新的靶标和药物，并强调参与者招募和研究设计的实际考虑。这篇综述还强调了帮助患者进入篮子试验的策略。随着篮子试验变得越来越普遍，确保公平实施这些研究的步骤对于分子靶向药物的开发至关重要.
